m ET
ENGLEWOOD, Colo. and GRAND PRAIRIE, Texas, Dec. 10, 2020 (GLOBE NEWSWIRE) Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, and Neos Therapeutics, Inc. (NASDAQ:NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that they have entered into a definitive merger agreement pursuant to which Neos will merge with a wholly owned subsidiary of Aytu in an all-stock transaction.
Transaction Details
Upon the effectiveness of the merger (the Merger ), Neos stockholders will be entitled to receive 0.1088 shares of common stock of Aytu for each share of Neos common stock held, after taking into account the one-for-ten reverse split of Aytu s common stock that was effected on December 8, 2020. The transaction will result in Neos stockholders owning approximately 30% of the fully diluted common shares o
The Price And Volume Action In Aytu BioScience's Stock Today Aytu BioScience (NASDAQ: AYTU) is currently up 26.35% to a price of $8.69. The stock’s current volume for the day is 3.76 million, which is approximately 1230.44% of its previous 30-day average volume of 305.25 thousand.
60 Stocks Moving In Thursday s Mid-Day Session Benzinga 12/10/2020
Gainers
Immutep Limited (NASDAQ: IMMP) shares jumped 198.6% to $6.42 after the company said its Chinese partner, EOC Pharma will commence a new Phase 2 clinical trial of Immutep s eftilagimod alpha in up to 152 metastatic breast cancer patients in China. Immutep said the study follows encouraging data reported by it in its APIAC Phase 2b study announced at the end of March and presented at the SABCS.
Greenwich LifeSciences, Inc. (NASDAQ: GLSI) shares surged 67.4% to $95.60. Greenwich LifeSciences shares jumped 998% on Wednesday after the company shared the poster for the GP2 Phase 2b clinical trial final efficacy analysis that was presented Wednesday at the 2020 San Antonio Breast Cancer Symposium.
/PRNewswire/ WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Neos Therapeutics,.